CRT 2025

Atherosclerosis and Lipids

Atherosclerosis and Lipids Summit

Pleotropic Effects of PCSK9 Inhibitors

Speaker(s)

• 

  Paul A. Gurbel, MD, FSCAI

  Director
  Sinai Center for Thrombosis Research and Drug Development
  Baltimore, Maryland, United States

  Disclosure information not submitted.